Fc engineering: Serum half-life modulation through FCRN binding

Methods in Molecular Biology

Volumn 907, Issue , 2012, Pages 537-556

  Olafsen, Tove ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Affinity and SEC chromatography; ELISA; Radioiodination; scFv Fc; Serial blood sampling; Site specific mutagenesis; Stable transfection

Indexed keywords

EID: 84867796429     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-974-7_31     Document Type: Article

References (31)

1. Jones EA, Waldmann TA (1972) The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest 51:2916-2927
2. Simister NE, Mostov KE (1989) An Fc receptor structurally related to MHC class I antigens. Nature 337:184-187
3. Brambell FW (1966) The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet 2:1087-1093
4. Ghetie V, Ward ES (2002) Transcytosis and catabolism of antibody. Immunol Res 25:97-113
5. Burmeister WP, Huber AH, Bjorkman PJ (1994) Crystal structure of the complex of rat neonatal Fc receptor with F.c. Nature 372:379-383
6. Martin WL, West AP Jr, Gan L et al (2001) Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 7:867-877
7. Rodewald R (1976) pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol 71:666-669
8. Jevsevar S, Kunstelj M, Porekar VG (2010) PEGylation of therapeutic proteins. Biotechnol J 5:113-128
9. Chaudhury C, Mehnaz S, Robinson JM et al (2003) The major histocompatibility complexrelated Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 197:315-322
10. Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132:171-183
11. Muller D, Karle A, Meissburger B et al (2007) Improved pharmacokinetics of recombinant bispeci fi c antibody molecules by fusion to human serum albumin. J Biol Chem 282: 12650-12660
12. Yazaki PJ, Kassa T, Cheung CW et al (2008) Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Biol 35:151-158
13. Kenanova VE, Olafsen T, Salazar FB et al (2010) Tuning the serum persistence of human serum albumin domain III: diabody fusion proteins. Protein Eng Des Sel 23:789-798
14. Evans L, Hughes M, Waters J et al (2010) The production, characterisation and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae. Protein Expr Purif 73:113-124
15. Smith BJ, Popplewell A, Athwal D et al (2001) Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem 12:750-756
16. Tijink BM, Laeremans T, Budde M et al (2008) Improved tumor targeting of antiepidermal growth factor receptor Nanobodies through albumin binding: taking advan tage of modular Nanobody technology. Mol Cancer Ther 7:2288-2297
17. Stork R, Campigna E, Robert B et al (2009) Biodistribution of a bispeci fi c single-chain diabody and its half-life extended derivatives. J Biol Chem 284:25612-25619
18. Stork R, Muller D, Kontermann RE (2007) A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispeci fi c single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel 20:569-576
19. Hopp J, Hornig N, Zettlitz KA et al (2010) The effects of af fi nity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng Des Sel 23:827-834
20. Huang C (2009) Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol 20:692-699
21. Reichert JM (2011) Antibody-based therapeutics to watch in 2011. MAbs 3:76-99
22. Kenanova V, Olafsen T, Williams LE et al (2007) Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res 67:718-726
23. Raghavan M, Bonagura VR, Morrison SL et al (1995) Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 34:14649-14657
24. Vaughn DE, Bjorkman PJ (1998) Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure 6:63-73
25. Medesan C, Matesoi D, Radu C et al (1997) Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol 158:2211-2217
26. Firan M, Bawdon R, Radu C et al (2001) The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol 13:993-1002
27. Shields RL, Namenuk AK, Hong K et al (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276:6591-6604
28. Kenanova V, Olafsen T, Crow DM et al (2005) Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 65: 622-631
29. Ober RJ, Radu CG, Ghetie V et al (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13: 1551-1559
30. Stout DB, Chatziioannou AF, Lawson TP et al (2005) Small animal imaging center design: the facility at the UCLA Crump Institute for Molecular Imaging. Mol Imaging Biol 7:393-402
31. Palmer BR, Marinus MG (1994) The dam and dcm strains of Escherichia coli-a review. Gene 143:1-12